LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, will present positive updated biomarker data from its Phase 1a/b TIMEPOINT study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback